Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of KB2115 (eprotirome) added to ezetimibe in primary hypercholesterolemia
2007-007831-24Phase 2Completed
- Sponsor
- Karo Healthcare AB
- Start
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hypercholesterolemia comparing KB2115 (eprotirome) add-on to ezetimibe with Placebo add-on to ezetimibe (2 arms). Primary endpoint: Change in LDL cholesterol from baseline to week 10. Started Jan 2008; status: completed.
02
Drugs
eprotirome
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on 2007-007831-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007831-24.